Compare FuelCell Energy Inc (FCEL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs ResMed Inc. — how do they compare? FuelCell Energy Inc trades at $17.27 (market cap $1.47B), while ResMed Inc. trades at $229.72 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 21.7× FuelCell Energy Inc's market cap, and ResMed Inc. pays a 1.16% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and ResMed Inc. for 51 Days on average.
| FCEL | RMD | |
|---|---|---|
Market Cap | $1.47B | $31.89B |
Volume | 12,559,948 | 618,314 |
Sector | Industrials | Health |
52-Week High | $36.01 | $277.88 |
52-Week Low | $6.00 | $182.82 |
Typical Hold Time | 48 Days | 51 Days |
Enterprise Value | $1.05B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $17.29, down 5.85% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported revenue of $158.16M for 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit and a 7% stock rally amid hydrogen sector interest.
The outlook remains cautious due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include profitability challenges and competitive pressures in the clean energy sector, while potential upside hinges on execution improvements and sector momentum.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
